3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
7
Head & Neck
3
Breast
3
Thoracic
2
Sarcoma
2
Gynecologic
2
Gastrointestinal
2
Myeloid
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
166
Endometrial Neoplasms
105
Uterine Cervical Neoplasms
89
Breast Neoplasms
58
Colorectal Neoplasms
45
Fallopian Tube Neoplasms
43
Carcinoma, Non-Small-Cell Lung
38
Pancreatic Neoplasms
34
Neoplasms
31
Prostatic Neoplasms
26
Stomach Neoplasms
25
Neoplasm Metastasis
25
Melanoma
24
Lung Neoplasms
22
Squamous Cell Carcinoma of Head and Neck
20
Esophageal Neoplasms
19
Carcinoma, Ovarian Epithelial
19
Urinary Bladder Neoplasms
17
Head and Neck Neoplasms
16
Carcinoma, Renal Cell
16
Triple Negative Breast Neoplasms
15
Sarcoma
15
Colonic Neoplasms
15
Carcinoma, Transitional Cell
14
Carcinoma, Hepatocellular
14
Peritoneal Neoplasms
13
Vulvar Neoplasms
12
Small Cell Lung Carcinoma
12
Rectal Neoplasms
12
Cholangiocarcinoma
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Gynecologic
×
30 days
×
Clear all
NCT06238479
2026-05-22
EXCEED
Eli Lilly and Company
Phase 1
Active not recruiting
490 enrolled
NCT06465069
2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1
Recruiting
420 enrolled